Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Enrolling by invitation · Phase 2, Phase 3 · NCT05248659
Conditions: Immunoglobulin A Nephropathy
At a glance
- Research payments reported, 2025
- $390,080
- U.S. investigators named
- 11
- Sites paid
- 11
- Planned or actual enrollment
- 600
About the trial
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Tested
- Sibeprenlimab 400 mg s.c. Q4weeks (drug)
- Dates
- Started 2022-04-05; completion 2029-12-31
- Results posted
- Not yet
To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN
From ClinicalTrials.gov, last updated 2026-05-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Otsuka Pharmaceutical Development & Commercialization, Inc. reported $390,080 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Dana Rizk Nephrology (Kidney) · Birmingham, AL
- Richard A. Lafayette, M.D. Nephrology (Kidney) · Stanford, CA
- Laura A. Kooienga, MD Nephrology (Kidney) · Denver, CO
- Edouard R. Martin, M.D. Nephrology (Kidney) · Lauderdale Lakes, FL
- Elizabeth T. Nguyen, M.D. Nephrology (Kidney) · Atlanta, GA
- James A. Tumlin, M.D. Nephrology (Kidney) · Lawrenceville, GA
- Ashar Luqman, M.D. Nephrology (Kidney) · Sioux City, IA
- Juan Carlos Q. Velez, MD Nephrology (Kidney) · New Orleans, LA
- Meghan E. Sise, M.D. Nephrology (Kidney) · Boston, MA
- Joel M. Topf, MD Nephrology (Kidney) · Roseville, MI
- Isabelle M. Ayoub, M.D Nephrology (Kidney) · Columbus, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Denver Nephrologists PC $115,201
- Dunes Clinical Research LLC $48,154
- The Ohio State University $38,082
- St Clair Nephrology Research LLC $37,487
- University of Alabama Hospital, AL $35,983
- Massachusetts General Hospital, MA $32,733
- Georgia Nephrology LLC $32,489
- The Board of Trustees of the Leland Stanford Junior University $18,281
- Fides Clinical Research LLC $15,820
- South Florida Research Institute $11,600
- Ochsner Medical Center Acute, LA $4,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.